ClinicalTrials.gg
RecruitingNCT04322734Updated Apr 23, 2026

Transgenerational Metabolic-Immune Biomarkers of Neurological and Neurodevelopmental Disorders

An observational study in Autism Spectrum Disorder, Mitochondrial Pathology and Epilepsy, sponsored by Southwest Autism Research & Resource Center. Recruiting at 2 sites in United States. Open to participants aged Up to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by Southwest Autism Research & Resource Center · Observational

How we know

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
Up to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 773 studies in Autism Spectrum Disorder with a site in United States — 163 open to participants now, 203 under way, 9 of them phase 3. Autism Spectrum Disorder · United States.

Planned enrollment
25th of 114
500 · median 132
Started
2023
with 56 others
Observational
114 of 773
23 open now
Primary completion
2028-12
later than 163 of 201 live
Registered
422nd of 773
by date

Among the 773 studies in Autism Spectrum Disorder with a site in United States, this one is the 25th largest by planned enrollment of the 114 observational ones that give a count, is one of 57 that started in 2023, is one of 114 observational ones, reaches primary completion later than 163 of the 201 other live ones, and was the 422nd registered.

Autism Spectrum Disorder

1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.

Browse Autism Spectrum Disorder studies →

Open to participants now

163 of the 773 studies in Autism Spectrum Disorder with a site in United States are open now. Recruiting first, the newest first:

158 more — sign in →

All 163 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 301 take children under 18; 92 take healthy volunteers.

This study: Up to 18 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 773 studies in Autism Spectrum Disorder with a site in United States, or all of them as a file.
02

Study summary

The study involves up to 5 visits for a fasting blood draw, behavioral assessments, and/or questionnaires. Other samples may be collected when appropriate.

This study is currently recruiting.

There is no cost for visits or study-related exams.

Read the detailed description

Mitochondria are essential for a wide range of functions in almost every cell in our body. Best known for their role in adenosine triphosphate (ATP) production, mitochondria are also closely involved in a wide variety of cell functions such as calcium buffering, redox regulation, apoptosis and inflammation, and regulate metabolism through several mechanisms, including epigenetic changes. ATP produced is essential for many cellular systems. Thus, abnormal mitochondrial function can adversely affect cellular systems by several mechanisms.

Given the important role of the mitochondria in cellular function, individuals with classic mitochondrial disease demonstrate devastating symptoms, particularly in tissues that have high-energy demands such as the brain, muscles, gastrointestinal (GI) tract and immune system. Mitochondrial dysfunction contributes to the pathophysiology of more common diseases, including psychiatric diseases, neurodegenerative disorders, neurological disorders including migraine and seizures, persistent systemic inflammation, cardiac disease, cancer and diabetes. Mitochondrial dysfunction also effects a significant portion of individuals with autism spectrum disorder (ASD) as well as genetic syndromes associated with ASD.

One of our goals is to develop a method using the Seahorse Analyzer to measure individual variations in mitochondrial function which can identify children with medical disorders and mitochondrial dysfunction without an invasive muscle biopsy. In order to establish comprehensive profiles of mitochondrial function for individuals with known neurological and neurodevelopmental disorders, we will compare blood, urine, and stool from these individuals to those of healthy, typically developing (TD) children. The relationship between mitochondrial function, development, and behavior will be assessed by performing standard developmental testing. In addition, in patients who have a procedure that produces leftover tissue, we will examine the mitochondrial function in that tissue and correlate it with findings from blood.

03

Conditions studied

  • Autism Spectrum Disorder
  • Mitochondrial Pathology
  • Epilepsy
  • Brain Tumor
  • Psychiatric Disorder
  • Mitochondrial Diseases
04

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

400 children aged 0 years to 17 years 11 months with a neurological, psychiatric or neurodevelopmental disorder.

250 children in this sample will have a known diagnosis of ASD: 50 children with a diagnosed MD (ASD/MD), 50 children with ruled out MD (ASD/NoMD), 150 children with ASD and unknown MD status.

Comparison groups: 50 children with epilepsy (without ASD), 50 with psychiatric disorders, 50 with brain tumors (without ASD) 50 with a diagnosed MD (without ASD)

Control group: 100 TD children (50 siblings of children with ASD and 50 without any siblings with ASD or developmental delay).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ASD, as defined by either a gold standard measure for ASD diagnosis, the Autism Diagnostic Observation Schedule (ADOS); the Autism Diagnostic Interview-Revised (ADI-R); and/or a comprehensive assessment that is consistent with ASD, in the opinion of the principal investigator. For those the PI believes a prospective diagnosis of ASD is warranted, a formal diagnostic assessment will be scheduled at screening.
  2. 0 years through 17 years 11 months of age

Inclusion Criteria (TD, MD, Epilepsy, Brain Tumor, Psychiatric)

1. 0 years to 17 years 11 months of age

Exclusion criteria

Exclusion Criteria (All):

  1. History of a significant adverse reaction to a prior blood draw
  2. In females of reproductive age, pregnancy or plans to become pregnant
  3. Any other historical event/information that may, in the opinion of the PI, be a reason to exclude the child from participation.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • ASD (General)

    150 children with ASD and unknown MD status

  • ASD (With MD)

    50 children with ASD and confirmed MD

  • ASD (No MD)

    50 children with ASD and ruled out MD

  • Epilepsy

    50 children with epilepsy (primary) and no ASD

  • Brain Tumor

    50 children with brain tumor (primary) and no ASD

  • Psychiatric Disorder

    50 children with psychiatric disorder (primary) and no ASD, using lithium treatments

  • MD (No ASD)

    50 children with MD (primary) and no ASD

  • TD (With ASD Sibling)

    50 TD children with a sibling with ASD/neurodevelopmental delay

  • TD (No ASD Sibling)

    50 TD children with no siblings with ASD/neurodevelopmental delay

06

What researchers measure

Primary outcomes

  1. Mitochondrial Reserve Capacity measured using the Seahorse XR Flux Analyzer

    Children with ASD will be differentiated from all other cohorts and have a specific pattern of mitochondrial dysfunction that will be different from and comparable to other groups of children in the study (e.g. mitochondrial disease without autism, typically developing, autism with mitochondrial disease, and developmental delay). It is hypothesized that these children will have a more pronounced delay in their development and will have a higher probability for poor developmental and behavioral outcomes. This will be evaluated using a Seahorse XR flux analyzer to generate a maximal reserve capacity value.

    Time frame: Up to one year

07

Study locations

2 of 2 sites recruiting
  • Southwestern Research and Resource Center
    Phoenix, Arizona 85016, United States
    Recruiting
    • Christopher J Smith, PhD · Contact(602) 218-8192
    • Sophia Crisler · Contact(480) 582-9467
    • Richard Frye, MD, PhD · Principal investigator
  • State University of New York, Downstate
    Brooklyn, New York 11203, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The PI may collaborate with other researchers to perform analyses on individual samples that have been stored for future research. In this case, the coded data with characteristics about the participant will be shared as appropriate (e.g., diagnostic status).

Time frame: After completion of initial study

Access criteria: Researchers must have an established protocol with relevant interest to the samples and data stored.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Dec 2028, 60 months after the start.

Of 98 non-industry observational studies under Autism Spectrum Disorder, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 120. This study's planned 60 months is above that.

Counting every sponsor, half of 112 studies reached it within 40 months; a quarter within 26 and three quarters within 120.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2020
First posted
Mar 26, 2020
StartActual
Dec 13, 2023
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04322734
Lead sponsor
Southwest Autism Research & Resource Center
Collaborators
State University of New York - Downstate Medical Center
Responsible party
Richard Frye (Principal Investigator and Sponsor, Southwest Autism Research & Resource Center) — Principal investigator
First posted
Mar 26, 2020
Start date
Dec 13, 2023
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Apr 23, 2026

Study contacts

Richard E Frye, MD, PhD
Contact
DrFrye@AutismDiscovery.org
844-ADTFRes
Richard E Frye, MD, PhD
study director · Autism Discovery & Treatment Foundation

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion